Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

Labcorp ® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio ® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C. , April 23, 2025 /PRNewswire/ --  Labcorp  (NYSE:

Labcorp Acquires Select Assets of North Mississippi Health Services’ Ambulatory Outreach Laboratory Business

Precision healthcare: The role of genetic testing and lab data in improving patient outcomes

Today, precision medicine provides a biological approach to treatment that considers a patient's genomic information, as well as environmental, lifestyle and social factors. Advancements in genomic testing are fundamentally changing care for cancer and other conditions. These exciting developments, under the umbrella of precision healthcare, are leading to more personalized healthcare delivery that offers competitive advantages to hospitals and health systems embracing this approach. These were key themes of an executive session sponsored by Labcorp at Becker's 12th Annual CEO + CFO Roundtable. In this discussion, three Labcorp leaders- Mahul B. Amin, MD, vice president and divisional medical director; Ken Cerney, vice president of commercial operations; and Ed Esplin, MD, PhD, clinical geneticist and medical director- focused on the role of lab data and genetic testing in the journey to precision medicine and personalized healthcare delivery.In August 2024, Invitae became part of Labcorp to further the future of genetic testing. With Invitae, Labcorp extends its leadership in specialty testing with the most comprehensive offerings in areas such as oncology and select rare diseases and advances its mission to improve health and improve lives.

Utilization of a SNP microarray to detect uniparental disomy: Implications and outcomes

Multiple Deletions In Chromosome 13 Mediated By Chromothripsis: A Case Report

Understanding prenatal chromosomal abnormalities;  importance of both chromosomal and microarray aberrations

Examination of prenatal cases referred for uniparental disomy 16:  Referral patterns, positive associations and key findings 

Case report: Incidental Diagnosis of Mulchandani-Bhoj-Conlin Syndrome by Prenatal Microarray

Expanding the fetal phenotype of USP7-related conditions

Safety testing capabilities and regulatory support to accelerate your novel food development

Regulatory requirements for food improvement agents are becoming increasingly stringent, requiring extensive testing to bring these products to market. Labcorp provides the comprehensive safety testing capabilities and regulatory expertise needed to navigate this complex landscape. As your partner, we help you accelerate the development of novel foods that address global nutritional challenges, enhance food quality and meet evolving consumer demands.